Research Analysts Offer Predictions for ANIX Q1 Earnings

Anixa Biosciences, Inc. (NASDAQ:ANIX) – Equities researchers at HC Wainwright issued their Q1 2026 earnings estimates for shares of Anixa Biosciences in a report issued on Tuesday, March 25th. HC Wainwright analyst Y. Chen forecasts that the company will earn ($0.10) per share for the quarter. HC Wainwright has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for Anixa Biosciences’ current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Anixa Biosciences’ Q2 2026 earnings at ($0.10) EPS, Q3 2026 earnings at ($0.10) EPS, Q4 2026 earnings at ($0.10) EPS and FY2026 earnings at ($0.40) EPS.

Anixa Biosciences (NASDAQ:ANIX) last announced its quarterly earnings data on Tuesday, March 11th. The company reported ($0.10) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.10).

A number of other brokerages also recently commented on ANIX. Maxim Group initiated coverage on Anixa Biosciences in a research report on Friday, March 21st. They set a “buy” rating and a $10.00 price objective for the company. D. Boral Capital reissued a “buy” rating and issued a $10.00 price objective on shares of Anixa Biosciences in a research report on Wednesday.

Anixa Biosciences Price Performance

Shares of NASDAQ ANIX opened at $3.15 on Wednesday. The company has a market cap of $101.42 million, a price-to-earnings ratio of -8.08 and a beta of 0.86. The stock’s 50-day moving average is $2.95 and its two-hundred day moving average is $3.01. Anixa Biosciences has a 1-year low of $2.07 and a 1-year high of $4.20.

Insider Transactions at Anixa Biosciences

In related news, Director Lewis H. Titterton, Jr. bought 10,000 shares of the stock in a transaction dated Friday, January 17th. The stock was acquired at an average price of $2.57 per share, for a total transaction of $25,700.00. Following the acquisition, the director now owns 922,334 shares in the company, valued at approximately $2,370,398.38. This represents a 1.10 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Amit Kumar purchased 43,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The shares were bought at an average price of $2.23 per share, for a total transaction of $95,890.00. Following the completion of the purchase, the chief executive officer now directly owns 559,925 shares in the company, valued at $1,248,632.75. This represents a 8.32 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders acquired 75,289 shares of company stock valued at $177,021. 25.30% of the stock is currently owned by corporate insiders.

Institutional Trading of Anixa Biosciences

Several institutional investors and hedge funds have recently made changes to their positions in ANIX. Millennium Management LLC acquired a new position in Anixa Biosciences during the fourth quarter worth approximately $26,000. Focus Partners Wealth purchased a new position in shares of Anixa Biosciences during the fourth quarter worth approximately $162,000. Jane Street Group LLC acquired a new position in shares of Anixa Biosciences in the 4th quarter valued at $67,000. Renaissance Technologies LLC raised its position in Anixa Biosciences by 36.5% in the 4th quarter. Renaissance Technologies LLC now owns 14,573 shares of the company’s stock valued at $34,000 after purchasing an additional 3,900 shares during the last quarter. Finally, LPL Financial LLC boosted its stake in Anixa Biosciences by 37.2% during the 4th quarter. LPL Financial LLC now owns 42,937 shares of the company’s stock worth $100,000 after purchasing an additional 11,633 shares during the period. 29.13% of the stock is owned by hedge funds and other institutional investors.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.